ACCRUFeR receives Authorisation by Korean Ministry

AI SummaryClose X

Shield Therapeutics plc (LSE: STX) announced on 07 November 2025 that its product, ACCRUFeR® (Ferric Maltol), received Marketing Authorisation from the Korean Ministry of Food and Drug Safety for treating iron deficiency in adults in South Korea. This approval, following a successful pharmacokinetic study and a 2024 New Drug Application by Korea Pharma, expands ACCRUFeR®'s global reach. Shield is now eligible to receive payments upon the first sale, performance-based sales milestones, and royalties on net sales in South Korea, a market where 5.2 million people suffer from iron deficiency or iron deficiency anemia. This development is expected to positively impact the company's revenue streams, leveraging a product already leading the US oral iron market.

Disclaimer*

UK 100

Latest directors dealings